Med. Pro Praxi 2007; 4(10): 402-405 [Prakt. lékáren. 2007; 3(3): 105-107]

Farmakoterapie revmatoidní artritidy (nová doporučení České revmatologické společnosti)

MUDr. Liliana Šedová
Revmatologický ústav, Praha

Nové zkušenosti s dopadem revmatoidní artritidy (RA) na nemocné a terapeutické možnosti získané v posledních 10 letech si vyžádaly změnu v léčebném postupu vůči tomuto chronickému zánětlivému onemocnění. Proto vznikla nová Doporučení České revmatologické společnosti, která zahrnují jak nově dostupné preparáty, tak i návrh nových algoritmů léčby u časné i etablované RA. Předpokladem správné léčby je časná diagnóza, hodnocení aktivity a prognózy a co nejčasnější zahájení agresivní léčby s pravidelným monitorováním účinnosti a bezpečnosti.

Keywords: revmatoidní artritida, časná artritida, chorobu modifikující léky, glukokortikoidy, biologické léky, antiTNF

Published: December 18, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Šedová L. Farmakoterapie revmatoidní artritidy (nová doporučení České revmatologické společnosti). Med. praxi. 2007;4(10):402-405.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-324. Go to original source... Go to PubMed...
    2. Brooks P, Emery P, Evans JF et al. Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2. Rheumatology 1999; 38: 779-783. Go to original source... Go to PubMed...
    3. Hochberg MC. Adult and juvenile rheumatoid arthritis: current epidemiological concepts. Epidemiol Ref 1981; 3: 27-44. Go to original source... Go to PubMed...
    4. Maini R, StClair EW, Breedveld F, et al. Infliximab (chimeric anti-tumor necrosis factor alfa monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999; 354: 1932-1939. Go to original source... Go to PubMed...
    5. Prevoo ML, van´t Hof MA, Kupper HH et al. Modified disease activity scores that include 28 joint counts: development and validation in a prospective longitudinal study in patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-48. Go to original source... Go to PubMed...
    6. Wassenberg S, Rau R, Steinfeld P, Ziedler H. Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double blind, placebo controlled trial. Arthritis Rheum 2005; 52: 3371-3380. Go to original source... Go to PubMed...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.